Acorda To Present New rHIgM22 and AMPYRA (dalfampridine) Data At The 31st Congress Of The European Committee For Treatment And Research In Multiple Sclerosis (ECTRIMS)

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq:ACOR) will present new analyses of pharmacokinetic data from a Phase 1 clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis (MS), and five-year post-marketing safety data on AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The meeting is being held in Barcelona, Spain, October 7 - 10.

Help employers find you! Check out all the jobs and post your resume.